These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 22001996)
21. Effects of myricetin, an anticancer compound, on the bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats. Li C; Lim SC; Kim J; Choi JS Eur J Drug Metab Pharmacokinet; 2011 Sep; 36(3):175-82. PubMed ID: 21442417 [TBL] [Abstract][Full Text] [Related]
22. Effects of silybinin, CYP3A4 and P-glycoprotein inhibitor in vitro, on the bioavailability of loratadine in rats. Li C; Lee MY; Choi JS Pharmazie; 2010 Jul; 65(7):510-4. PubMed ID: 20662320 [TBL] [Abstract][Full Text] [Related]
23. Effects of morin on the pharmacokinetics of nicardipine after oral and intravenous administration of nicardipine in rats. Piao YJ; Choi JS J Pharm Pharmacol; 2008 May; 60(5):625-9. PubMed ID: 18416939 [TBL] [Abstract][Full Text] [Related]
24. Effects of licochalcon A on the pharmacokinetics of losartan and its active metabolite, EXP-3174, in rats. Choi JS; Choi JS; Choi DH Pharmazie; 2013 Nov; 68(11):882-8. PubMed ID: 24380237 [TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic interaction between oral lovastatin and verapamil in healthy subjects: role of P-glycoprotein inhibition by lovastatin. Choi DH; Chung JH; Choi JS Eur J Clin Pharmacol; 2010 Mar; 66(3):285-90. PubMed ID: 20012601 [TBL] [Abstract][Full Text] [Related]
26. Effect of hesperidin on the oral pharmacokinetics of diltiazem and its main metabolite, desacetyldiltiazem, in rats. Cho YA; Choi DH; Choi JS J Pharm Pharmacol; 2009 Jun; 61(6):825-9. PubMed ID: 19505375 [TBL] [Abstract][Full Text] [Related]
27. Effects of licochalcone A on the bioavailability and pharmacokinetics of nifedipine in rats: possible role of intestinal CYP3A4 and P-gp inhibition by licochalcone A. Choi JS; Choi JS; Choi DH Biopharm Drug Dispos; 2014 Oct; 35(7):382-90. PubMed ID: 24903704 [TBL] [Abstract][Full Text] [Related]
28. Strategy to Improve the Oral Pharmacokinetics of Cyclin-Dependent Kinase 4/6 Inhibitors: Enhancing Permeability and CYP450 Inhibition by a Natural Bioenhancer. Patil PH; Desai MP; Rao RR; Mutalik S; Puralae Channabasavaiah J AAPS PharmSciTech; 2024 Aug; 25(6):181. PubMed ID: 39117933 [TBL] [Abstract][Full Text] [Related]
29. Effects of lovastatin on the pharmacokinetics of verapamil and its active metabolite, norverapamil in rats: possible role of P-glycoprotein inhibition by lovastatin. Hong SP; Chang KS; Koh YY; Choi DH; Choi JS Arch Pharm Res; 2009 Oct; 32(10):1447-52. PubMed ID: 19898809 [TBL] [Abstract][Full Text] [Related]
30. Effects of HMG-CoA reductase inhibitors on the pharmacokinetics of losartan and its main metabolite EXP-3174 in rats: possible role of CYP3A4 and P-gp inhibition by HMG-CoA reductase inhibitors. Yang SH; Choi JS; Choi DH Pharmacology; 2011; 88(1-2):1-9. PubMed ID: 21709429 [TBL] [Abstract][Full Text] [Related]
31. Effect of resveratrol on the pharmacokinetics of oral and intravenous nicardipine in rats: possible role of P-glycoprotein inhibition by resveratrol. Choi JS; Choi BC; Kang KW Pharmazie; 2009 Jan; 64(1):49-52. PubMed ID: 19216231 [TBL] [Abstract][Full Text] [Related]
32. Effects of resveratrol on the pharmacokinetics of diltiazem and its major metabolite, desacetyldiltiazem, in rats. Hong SP; Choi DH; Choi JS Cardiovasc Ther; 2008; 26(4):269-75. PubMed ID: 19035878 [TBL] [Abstract][Full Text] [Related]
33. Enhanced oral exposure of diltiazem by the concomitant use of naringin in rats. Choi JS; Han HK Int J Pharm; 2005 Nov; 305(1-2):122-8. PubMed ID: 16226412 [TBL] [Abstract][Full Text] [Related]
34. Baicalein inhibits the pharmacokinetics of simvastatin in rats Meng M; Li X; Zhang X; Sun B Pharm Biol; 2021 Dec; 59(1):880-883. PubMed ID: 34214011 [TBL] [Abstract][Full Text] [Related]
35. Effect of Atorvastatin on Single Oral Pharmacokinetics and Safety of Daclatasvir in Rats: Emphasis on P-glycoprotein and Cytochrome P450. Elbadawy HA; Wahdan SA; El-Demerdash E Curr Drug Metab; 2022; 23(6):484-495. PubMed ID: 35379125 [TBL] [Abstract][Full Text] [Related]
36. Effects of silibinin, inhibitor of CYP3A4 and P-glycoprotein in vitro, on the pharmacokinetics of paclitaxel after oral and intravenous administration in rats. Lee CK; Choi JS Pharmacology; 2010; 85(6):350-6. PubMed ID: 20523105 [TBL] [Abstract][Full Text] [Related]
37. Effects of epigallocatechin gallate on the oral bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats. Shin SC; Choi JS Anticancer Drugs; 2009 Aug; 20(7):584-8. PubMed ID: 19491656 [TBL] [Abstract][Full Text] [Related]
38. Enhanced oral bioavailability of felodipine by naringenin in Wistar rats and inhibition of P-glycoprotein in everted rat gut sacs in vitro. Surya Sandeep M; Sridhar V; Puneeth Y; Ravindra Babu P; Naveen Babu K Drug Dev Ind Pharm; 2014 Oct; 40(10):1371-7. PubMed ID: 23883365 [TBL] [Abstract][Full Text] [Related]
39. Involvement of cytochrome P450 3A4 and P-glycoprotein in first-pass intestinal extraction of omeprazole in rabbits. Fang HM; Xu JM; Mei Q; Diao L; Chen ML; Jin J; Xu XH Acta Pharmacol Sin; 2009 Nov; 30(11):1566-72. PubMed ID: 19820718 [TBL] [Abstract][Full Text] [Related]